Sign In
Buy BETRF
$0.0471
+0.0041 (+9.53%)
At Close: Jun 03, 2026
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
08:00am, Thursday, 20'th Apr 2023
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focu
BetterLife Pharma says BETR-001 drug candidate featured in Drug Discovery & Development article
09:31am, Wednesday, 29'th Mar 2023
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies,” based on BetterLife's lea
BetterLife Pharma closes $1.5M private placement
01:57pm, Tuesday, 14'th Mar 2023
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced the closing of a brokered private placement worth $1.5 million. The company is offering 15 million units at a price of $0.10 per unit, wit
Betterlife Pharma's reports positive study findings for lead candidate BETR-001
09:27am, Thursday, 09'th Mar 2023
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) revealed promising findings from a study on its lead candidate BETR-001 (2-bromo-LSD), a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative mo
BetterLife Pharma unveils plans for a private placement offering of units
06:43am, Wednesday, 08'th Mar 2023
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced plans for a private placement offering of units, comprising of one common share and one common share purchase warrant of the company. Bloom
BetterLife Pharma hires strategic advisory services firm to support development toward clinical trials of its psychedelic compounds
09:16am, Thursday, 26'th Jan 2023
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has engaged Bloom Burton Securities Inc for strategic advisory services to support its growth and development initiatives toward clinica
BetterLife Pharma closes private placement with help from Negev Capital to fuel clinical programs
09:42am, Wednesday, 07'th Dec 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has closed a financing designed to advance its clinical and preclinical studies. The non-brokered private placement included 3,160,000 s
BetterLife to present BETR-001 preclinical data at the American College of Neuropsychopharmacology meeting in Phoenix
09:25am, Friday, 02'nd Dec 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton University's Department of Neuroscience, will make a presentation on
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focus
BetterLife Pharma files comprehensive patent for BETR-001 and other LSD derivatives
08:58am, Tuesday, 27'th Sep 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has filed a PCT patent application along with a US application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD. The appli
BetterLife Pharma and collaborators to submit key joint research on BETR-001 to publication
09:39am, Wednesday, 07'th Sep 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF), which is focused on the development of treatments for mental disorders, revealed that it is working with its collaborators on a key research publication
BetterLife Pharma says new study of LSD validates the cognitive effects of its analog drug BETR-001
09:10am, Wednesday, 24'th Aug 2022
A recent study of the nootropic effects of LSD, published in the scientific journal Experimental Neurology, is validating for BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) and its LSD analog BETR-001,
BetterLife Pharma secures additional Mitacs funding for BETR-001 preclinical depression studies
08:44am, Wednesday, 06'th Jul 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has secured additional Mitacs funding for preclinical depression studies on its LSD-derivative molecule BETR-001. The Vancouver-based biotechnol
BetterLife Pharma to present BETR-001 preclinical data at FENS Forum in Paris, France in July
09:31am, Tuesday, 21'st Jun 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an abstract covering the anti-depressant activity of its lead compound 2-bromo-LSD (BETR-001) has been accepted for poster presentati
BetterLife to present BETR-001 preclinical data at Canadian Association for Neuroscience Conference
10:02am, Thursday, 21'st Apr 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an abstract from the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD (BETR-001) has been accepted for p
